Study objective: To determine the additive effect of oral theophylline in patients with stable COPD who received both inhaled salbutamol, 400 jig, and ipratropium bromide, 80 gg, four times daily administered with a metered-dose inhaler. Design: Twenty-four male patients with stable COPD (FEVI, 0.96 + 0.43 L; 36.8 ± 17.0 percent predicted [% pred]) completed a randomized, double-blind, placebo-controlled crossover trial with oral theophylline for 4 weeks. Measurements and results: The average serum theophylline level was 15.0±5.5 ,g/mL during treatment.
The bronchodilating effect of oral theophylline is inferior to that of inhaled bronchodilators.1 '6 Therefore, for patients with stable chronic obstructive pulmonary disease (COPD), recent therapeutic recommendations suggest that theophylline should be used only as a third-choice drug if combined inhaled anticholinergic agent and inhaled f2-agonist fail to improve a patient's condition.7-9 However, some controversy exists as to whether the effect of theophylline is additive on that of the inhaled bronchodilators. Another complicating factor is that a Kawara- machi, Shogoin, Sakyoku, Kyoto 606, Japan they were thus considered subjective responders. While FEV1 after inhalation was significantly improved during the theophylline periods in subjective responders (change in FEV1 between theophylline and placebo treatment 15 min after inhalation, 3 .1 %pred; 60 min, 3.5 %pred), postbronchodilator FEV1 was not significantly different between the placebo and theophylline periods in subjective nonresponders (15 min, 1.7 %pred; 60 min, 1.6 
%pred).
Conclusions: On the whole, theophylline has a small bronchodilating effect but does not improve the symptoms of patients with stable COPD. However, one third of patients with COPD may respond subjectively to theophylline. The additive bronchodilating effect of theophylline may be related to the symptomatic improvement in subjective responders.
( that oral theophylline had an additive bronchodilating effect when used with inhaled salbutamol, 200
,ug, and ipratropium bromide, 40 Ag, but improvements in the symptoms were not observed. 27 If larger doses of the /2-agonist and anticholinergic agent had been used, the additive bronchodilator effect of theophylline may not have occurred.
The purpose of the present study was to determine the additive effect of oral theophylline in patients who received a high-dose combination of inhaled anticholinergic agent and inhaled /32-agonist. Patients with stable COPD completed a randomized, double-blind, placebo-controlled crossover trial with oral theophylline for 4 weeks. To ensure that sufficient bronchodilators were inhaled to achieve near maximum bronchodilating effect, all patients continued to take both salbutamol, 400 ,g, and ipratropium bromide, 80 ,tg, using a metered-dose inhaler (MDI) with a spacer device four times a day throughout the study period.
MATERIALS AND METHODS

Patient Selection
Thirty ibility of FEV, to 400 gg of salbutamol was measured after these pulmonary function tests. The drug was administered in four puffs from a MDI using the spacer device and spirometry was measured before and 15 min after inhalation. Sustained-release theophylline and matching placebo (Rh6ne-Poulenc Rorer Japan, Tokyo) were each administrated for a 4-week period in a randomized, double-blind, placebo-controlled crossover fashion (Fig 1) . The daily doses of theophylline were predetermined to provide average serum concentrations of more than 10 ,g/mL and matching quantities of placebo were given. All of the patients continued to inhale both salbutamol (400 ,ug in four puffs) and ipratropium bromide (80 ,ug in four puffs) using an MDI four times a day throughout the study period. Treatment with all other drugs was withheld for at least 2 weeks prior to and during the study period.
The patients visited the outpatient clinic around the same time at 4-week intervals. Inhalation was stopped at least 12 h before every visit. To ensure that the drugs were administered during deep inspirations, the inhalation technique was carefully observed by the same physician (K.N.). This physician also carefully observed all of the spirometric measurements. Blood samples for the assay of theophylline were collected at each visit and stored until the study was completed. Serum theophylline concentrations were determined by fluorescence polarization immunoassay using an analyzer (TDx, Dainabot, Tokyo).
Outcome Measures
Acute bronchodilator responses to the inhaled bronchodilators were measured at every visit to the clinic. Spirometry was assessed before, and 15 and 60 min after the inhalation of both salbutamol, 400 Ag (four puffs), and ipratropium bromide, 80 jug (four puffs), using an MDI with a spacer device. Three consecutive flow-volume curves were recorded, according to vere), were noted in a diary, and side effects were also recorded during the entire study period. 27 The PEFR readings, daily symptom scores, and side effects were assessed for the last 14 days of each 4-week period. At the end of the study, all patients were asked to compare the two different treatment periods with respect to clinical well-being. If a patient did not find any difference in symptoms between the two treatment periods, he was considered a subjective nonresponder. If a patient felt much better during one side treatment period and much worse during another treatment period and his selection was compatible with theophylline treatment after the regimens were revealed, we defined him as a subjective responder. If his preference did not correspond to the theophylline treatment after the regimens were revealed, he was also defined as a subjective nonresponder.
Statistical Analysis
All data are expressed as the mean ± SD. The significance of differences between values observed during treatment with theophylline and the placebo was determined by repeated measured analysis of variance. When appropriate, means were compared using the paired t test (two-
RESULTS
Seven patients who began the study did not finish it. One patient was withdrawn because he complained of urinary tract infection apparently unrelated to the study. Four patients dropped out of the study because of exacerbation due to respiratory tract infection: two during the theophylline period and two during the placebo period. While receiving treatment with theophylline, two patients discontinued its use because of gastrointestinal side effects. Twenty-five male patients completed the entire study. Since theophylline was not detected in the blood during the theophylline period in one patient, he was excluded from the data analysis. Consequently, a total of 24 patients were evaluated.
The baseline clinical data for the 24 Table 2) . At the end of the study period, 15 patients did not recognize any symptomatic differences during the two crossover periods with active or placebo administration (subjective nonresponders). Nine patients reported symptomatic improvement during one of the two treatment periods. Since one of nine patients preferred the placebo period to the theophylline period, he was classified as a subjective nonresponder. The other eight patients were classified as subjective responders.
For these eight subjective responders, all the values of FEV1 measured before and 15 and 60 min after the inhalation were significantly different between the placebo and theophylline periods (change in FEV1 between theophylline and placebo treatment 15 min after inhalation, 3.1 % pred; 60 min, 3.5 %pred) (Table 3) . However, for 16 subjective nonresponders, FEV1 values were not significantly different between the placebo and theophylline periods at 15 and 60 min after inhalation (15 min, 1.7 %pred; 60 min 1.6 %pred), although theophylline significantly improved FEV1 at the preinhalation evaluation. When FVC, daily home PEFR, and symptom scores were analyzed separately for subjective responders and for nonresponders, the results were similar to those obtained when all patients were grouped together. Furthermore, none of the baseline clinical characteristics shown in Table 1 or the serum theophylline level was significantly different between subjective responders and nonresponders. Sixteen patients (67%) complained of gastrointestinal side effects while receiving theophylline and 10 patients (42%) reported similar adverse effects during placebo administration. By counting the number of days that gastrointestinal side effects were reported, we found that theophylline was significantly associated with anorexia or nausea when compared with Dose-dependent bronchodilation also makes it difficult to discriminate between irreversible and reversible airflow limitation. Although reversibility in FEV1 was not included as an entry criterion in the present study, we carefully selected patients with long-standing COPD. All the patients had been followed up over several months in our hospital. At the start of this study, we measured bronchodilator responses after the inhalation of salbutamol, 400 ,tg, using an MDI. Although FEV1 after bronchodilator inhalation was on average 121% of the prebronchodilator value, similar bronchodilator responses have been reported in some previous studies on COPD.3234 The clinical and physiologic improvements noted with inhaled bronchodilators are usually associated with the small but statistically significant increases in FEVI.
Oral theophylline has been used for several decades as a bronchodilator. In addition, theophylline may improve diaphragmatic contractility36'37 and respiratory muscle performance,38 produce a sustained but modest enhancement of cardiac biventricular performance,39 and reduce the dyspnea sensation.40 However, none of our patients, even those who felt symptomatic benefit from theophylline (subjective responders), reported significant changes in their daily symptom scores. To our knowledge, there has been little evidence that oral theophylline treatment improved daily symptom scores.27 '41-43 Daily symptom scores, such as the four-grade score that we used, may not be sensitive enough to monitor patient symptoms adequately. Therefore, the assessment of symptoms and subjective improvement could have been strengthened in the present study by using objective measurements of the patient's exercise tolerance such as a 6-min walk or a Borg or visual analog scale with standardized tasks to evaluate dyspnea on exercise. The inclusion of a quality-of-life scale to determine if any improvement was counterbalanced by adverse effects would have been useful.
Kirsten et a144 conducted a study on theophylline therapy withdrawal and found that about half of the patients with severe COPD can be considered theophylline responders. They also suggested that the clinical effectiveness of this drug cannot be attributed exclusively to bronchodilation. In the present study, while FEV1 after inhalation was significantly improved during periods of theophylline treatment in subjective responders, postbronchodilator FEV1 was not significantly different between the placebo and theophylline periods in subjective nonresponders.
This finding suggests that the additive bronchodilating effect of oral theophylline is related to the symptomatic improvement in subjective responders and also suggests that daily symptom scores used in the present study did not reflect the symptomatic improvement in subjective responders.
Filuk et a14 reported that inhaled salbutamol and intravenous aminophylline are additive as bronchodilators in patients with COPD. However, Georgopoulos et al45 found that intravenous salbutamol and aminophylline did not have a significant additive bronchodilating effect. The latter authors suggested that the distribution of the drugs could be different with inhaled and intravenous routes of administration.45 Thus, differential distribution of inhaled and orally administrated drugs may account for our observation of an additive effect of oral theophylline when used in conjunction with a high dose of inhaled bronchodilators.
In conclusion, since theophylline has a small bronchodilating effect but does not improve the symptoms of patients with stable COPD, the usefulness of oral theophylline in combination with a high dose of inhaled bronchodilators is doubtful. However, when theophylline is used with adequate amounts of inhaled bronchodilators, our results suggest that one third of the patients with stable COPD may respond to theophylline. The additive bronchodilating effect of oral theophylline may be related to this symptomatic improvement in subjective responders. Since gastrointestinal side effects are frequently associated with theophylline administration, not all patients with COPD should receive theophylline and continuation of theophylline treatment should be considered only for patients who feel better. For individual patients with COPD, it would be worthwhile to perform a trial with theophylline to see if symptomatic improvement occurs before theophylline is continuously prescribed. ropium bromide and theophylline in chronic obstructive pulmonary disease. Am J Med 1991; 91(suppl 4A):24S-27S 7 Gross NJ. Chronic bronchitis and emphysema. In: Cherniack
